Erythropoietin for treatment cerebral vasospasm after subarachnoid hemorrhage and its effect on the expression of regulating nuclear factor kappa B in rabbits

Hong-xia YIN,Xin-feng LIU,Ji-xin SHI,Xin HUANG,Gang CHEN,Meng QI,Jin-song LI

DOI: https://doi.org/10.3969/j.issn.1672-5921.2008.09.006

2008-01-01

Abstract:Objective: To investigate the efficacy of erythropoietin (EPO) in delayed cerebral vasospasm following subarachnoid hemorrhage (SAH) and its regulatory effect on the expression of nuclear factor kappa B (NF-κB) in rabbits. Methods: A total of 36 male New Zealand white rabbits were selected, and they were randomly allocated into control, SAH, and EPO groups (n = 12 in each group). Delayed cerebral vasospasm was induced by using a SAH model of injecting autologous blood into the cisterna magna. The dose of EPO was 1000 IU/(kg · 8 h), and it was injected intraperitoneally for 5 days. The animals were killed 5 days after the model established. Their basilar arteries were obtained and the cross-section area was detected by HE staining. The NF-κB binding activity was detected by electrophoretic mobility shift assay (EMSA). Results: 1 The lumen's cross-sectional areas of basilar arteries in the control, SAH and EPO groups were 0.412 ± 0.034, 0.210 ± 0.018, and 0.342 ± 0.030 mm2, respectively. There was significant difference between the SAH and the control groups (P <0.01), and between the EPO and the SAH groups (P <0.01). There was also significant difference between the EPO and the control groups (P <0.05). 2 The gray values of NF-κB activity in the 3 groups were 1.20 ± 0.11, 9.30 ± 1.12, and 6.60 ± 0.13, respectively. There were significant differences between the SAH and the control groups, and between the EPO, control and SAH groups (P <0.01). Conclusion: EPO may relieve delayed cerebral vasospasm after SAH, and inhibit the expression of NF-κB in cerebral arteries after SAH.